Navigation Links
FFF Named the Exclusive Distributor of Fluzone for GPOs & Announces New Fluzone Return Policy

The nation’s most trusted distributor of plasma products, vaccines and critical-care biopharmaceuticals announces exclusive sanofi pasteur Fluzone® agreement for select GPOs, as well as new Fluzone® return policy.

(Vocus) April 6, 2009 -- As a trusted partner in the flu vaccine distribution marketplace, FFF Enterprises, Inc., is pleased to announce that sanofi pasteur has named FFF the exclusive Fluzone® distributor for the following GPO contracts: Amerinet, Broadlane, HealthTrust, MedAssets, MHA, Novation and Premier. “Sanofi pasteur is a longtime valued manufacturing partner, and we are honored to be its exclusive distributor of Fluzone® for these GPO contracts,” states Patrick M. Schmidt, chief executive officer, FFF Enterprises, Inc.

In addition, FFF announced it is now offering lowered pricing for Fluzone®, and has introduced a return guarantee for this product. Under the new Fluzone® return policy, customers may return up to 25 percent of full, unopened vials or boxes of Fluzone purchased from FFF for a full refund. “We have a legacy of providing solutions that mitigate and/or remove risks for our customers, and the new Fluzone® return policy helps healthcare workers on the front line prepare for flu season without the risk of holding leftover inventory at the end of the season,” continues Schmidt.

It is this kind of commitment to what the company calls “Wow! Customer Care!” that has made FFF a respected industry leader for over 21 years. FFF has dedicated more than two decades to building collaborative relationships with its GPO partners to assure a mutual benefit from FFF’s extensive marketplace reach, fair pricing and availability of product. The announcement of these exclusive contracts demonstrates the quality of the relationships FFF has established with its manufacturing partners.

Customers can order their Fluzone® online at or by phone or fax, with the confidence of knowing their vaccine will arrive on time, and that they will not have to worry about excess inventory.

About FFF Enterprises, Inc.

FFF Enterprises, Inc., a privately held corporation, is the largest and most trusted distributor of plasma products, vaccines and other biopharmaceuticals in the U.S. Founded in 1988, FFF is celebrating its 21st year with more than a billion dollars in annual sales and a flawless safety track record. FFF’s Guaranteed Channel Integrity™ ensures that products are purchased only from the manufacturer and shipped only to healthcare providers, protecting patients and manufacturers from counterfeit risks and pricing irregularities inherent in secondary and gray market channels. FFF’s proprietary technologies, Verified Electronic Pedigree™ and Lot-Track™, provide verification of this secure channel. FFF’s MyFluVaccine ( has revolutionized the flu marketplace, offering a dedicated flu vaccine supply, delivered to customers on the date of their choosing, and offering certainty in a volatile market segment. FFF’s ability to move rapidly in a dynamically changing marketplace allows the creation of new opportunities for customers through innovative vehicles for distribution.

# # #

Read the full story at

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. James M. Sweeney Named Chairman and CEO of IntelliDOT
2. KGBTexas Named Public Relations Agency of Record for PurinaCare(R) Pet Health Insurance
3. NorthShore University HealthSystem Named One of the Nation's Top 100 Hospitals by Thomson Reuters
4. iVisit Named Finalist in CTIA Wireless 2009(R) CTIA E-Tech Awards for Innovation in Enterprise & Vertical - Healthcare Solution
5. Central DuPage Hospital Named a 100 Top Hospital in the U.S. for Third Consecutive Year
6. Dr Howard Holtz Named New Jersey Top Doctor for Third Consecutive Year
7. 2 NYU scientists named Howard Hughes Medical Institutes Early Career Scientists
8. Three New Trustees Named By March of Dimes Foundation
9. Two NYU Scientists Named Howard Hughes Medical Institutes early career scientists
10. QHR Management Client Hancock Medical Center Named Mississippi Hospital of the Year
11. Three Johns Hopkins researchers named Howard Hughes Medical Institute early career scientists
Post Your Comments:
Related Image:
FFF Named the Exclusive Distributor of Fluzone for GPOs & Announces New Fluzone Return Policy
(Date:6/27/2016)... ... June 27, 2016 , ... ... patient payment industry today announced its strategic partnership with Connance, a healthcare ... , The two companies’ proven, proprietary technology combine to provide health systems, ...
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a ... can give their videos a whole new perspective by using the title layers ... Film Studios. , ProSlice Levels contains over 30 Different presets to choose from. ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... Austin ... of the American College of Mohs Surgery and to Dr. Russell Peckham for medical ... and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
(Date:6/24/2016)... , ... June 24, 2016 , ... June 19, 2016 ... dangers associated with chronic pain and the benefits of holistic treatments, Serenity Recovery ... are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/23/2016)... HILLS, Calif. , June 23, 2016 Any ... the many challenges of the current process. Many of them ... because of the technical difficulties and high laboratory costs involved. ... have to offer it at such a high cost that ... afford it. Dr. Parsa Zadeh , founder ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
Breaking Medicine Technology: